Brokerages expect ABIOMED, Inc. (NASDAQ:ABMD) to post earnings of $1.07 per share for the current quarter, Zacks reports. Six analysts have provided estimates for ABIOMED’s earnings. The highest EPS estimate is $1.13 and the lowest is $1.03. ABIOMED reported earnings per share of $0.80 in the same quarter last year, which indicates a positive year over year growth rate of 33.8%. The firm is scheduled to issue its next quarterly earnings results on Thursday, May 2nd.

On average, analysts expect that ABIOMED will report full year earnings of $5.05 per share for the current financial year, with EPS estimates ranging from $4.97 to $5.09. For the next fiscal year, analysts forecast that the business will post earnings of $4.94 per share, with EPS estimates ranging from $4.73 to $5.44. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow ABIOMED.

ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings results on Thursday, January 31st. The medical equipment provider reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.03. The company had revenue of $200.56 million for the quarter, compared to analyst estimates of $200.60 million. ABIOMED had a net margin of 30.12% and a return on equity of 20.31%.

Several equities research analysts recently issued reports on ABMD shares. Zacks Investment Research raised shares of ABIOMED from a “hold” rating to a “buy” rating and set a $370.00 price target on the stock in a report on Friday, January 18th. ValuEngine downgraded shares of ABIOMED from a “buy” rating to a “hold” rating in a research report on Tuesday, November 20th. Morgan Stanley cut their target price on shares of ABIOMED from $496.00 to $461.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 2nd. Finally, BidaskClub downgraded shares of ABIOMED from a “buy” rating to a “hold” rating in a research report on Wednesday, January 30th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. ABIOMED presently has an average rating of “Buy” and a consensus price target of $421.00.

Shares of ABIOMED stock traded down $0.02 during midday trading on Thursday, hitting $325.61. 199,636 shares of the company traded hands, compared to its average volume of 477,456. The firm has a market capitalization of $14.66 billion, a PE ratio of 132.90, a price-to-earnings-growth ratio of 3.27 and a beta of 0.37. ABIOMED has a 12 month low of $274.02 and a 12 month high of $459.75.

In related news, Director Martin P. Sutter sold 5,000 shares of ABIOMED stock in a transaction that occurred on Wednesday, February 13th. The shares were sold at an average price of $360.00, for a total transaction of $1,800,000.00. Following the sale, the director now directly owns 195,491 shares in the company, valued at approximately $70,376,760. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Martin P. Sutter sold 5,985 shares of ABIOMED stock in a transaction that occurred on Wednesday, February 6th. The stock was sold at an average price of $349.49, for a total transaction of $2,091,697.65. Following the sale, the director now owns 212,943 shares in the company, valued at $74,421,449.07. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 74,928 shares of company stock worth $26,515,812. 3.50% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Marathon Capital Management lifted its position in shares of ABIOMED by 4.0% in the 4th quarter. Marathon Capital Management now owns 780 shares of the medical equipment provider’s stock worth $253,000 after purchasing an additional 30 shares during the period. Kornitzer Capital Management Inc. KS lifted its position in shares of ABIOMED by 0.5% in the 4th quarter. Kornitzer Capital Management Inc. KS now owns 6,930 shares of the medical equipment provider’s stock worth $2,253,000 after purchasing an additional 35 shares during the period. Bbva Compass Bancshares Inc. lifted its position in shares of ABIOMED by 3.7% in the 4th quarter. Bbva Compass Bancshares Inc. now owns 1,417 shares of the medical equipment provider’s stock worth $461,000 after purchasing an additional 50 shares during the period. Equitable Trust Co. lifted its position in shares of ABIOMED by 2.1% in the 4th quarter. Equitable Trust Co. now owns 2,450 shares of the medical equipment provider’s stock worth $796,000 after purchasing an additional 50 shares during the period. Finally, Cornerstone Advisors Inc. lifted its position in shares of ABIOMED by 304.8% in the 4th quarter. Cornerstone Advisors Inc. now owns 85 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 64 shares during the period. Hedge funds and other institutional investors own 86.96% of the company’s stock.

About ABIOMED

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Further Reading: Asset Allocation and Your Retirement

Get a free copy of the Zacks research report on ABIOMED (ABMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.